Table 1.
Baseline characteristics of the included AS patients (N = 122), specified for gender
| Overall | Female | Male | P‐value (if possible 95% CI) | |
|---|---|---|---|---|
| Population, n (%) | 122 (100) | 48 (39.3) | 74 (60.7) | |
| Mean age in years (range) | 43.5 (17–75) | 43.7 (17–75) | 43.4 (20–68) | 0.88 (−4.8–4.1) |
| HLA‐B27+ (%) | 91.7 | 89.6 | 93.2 | 0.24 |
| TNFi treatment, n (%) | 0.02a | |||
| Adalimumab | 95 (59.7) | 19 (28.4) | 27 (29.3) | |
| Etanercept | 46 (28.9) | 35 (52.2) | 60 (65.2) | |
| Infliximab | 18 (11.3) | 13 (19.4) | 5 (5.4) | |
| Co‐medication used n (%) | 0.69 | |||
| NSAIDs | 51 (41.8) | 19 (39.6) | 32 (43.2) | |
| DMARDs | 12 (9.8) | 5 (10.4) | 7 (9.5) | |
| Phenylbutazone | 6 (4.9) | 2 (1.6) | 4 (3.3) |
Except indicated otherwise, values were presented as n (%); TNFI, tumor necrosis factor α inhibitor; HLA‐B27+, presence of human leukocyte antigen B27; AS, ankylosing spondylitis; NSAIDs, non‐steroidal anti‐inflammatory drugs; DMARDs, disease‐modifying anti‐rheumatic drugs, methotrexate and sulfasalazine.
a
Significant difference.